Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evolocumab + routine lipid management
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
evolocumab + routine lipid management refers to a therapeutic regimen combining the PCSK9 inhibitor evolocumab (Repatha) with standard-of-care lipid-lowering treatments. This combination is the focus of Amgen's EVOLVE-MI clinical trial, which investigates the impact of early evolocumab administration in patients hospitalized for acute myocardial infarction (STEMI or NSTEMI). Evolocumab is a fully human monoclonal antibody that binds to PCSK9, preventing it from mediating the degradation of LDL receptors, thereby increasing the clearance of LDL cholesterol from the blood. Routine lipid management typically includes the administration of HMG-CoA reductase inhibitors (statins) and may include NPC1L1 inhibitors like ezetimibe. The regimen aims to reduce the risk of major adverse cardiovascular events (MACE) in the high-risk post-infarction period.
- Brand names
- Repatha
- Other names
- routine lipid management-Amgen-myocardial infarctionevolocumabEVOLVE-MI intervention
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on evolocumab + routine lipid management.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evolocumab + routine lipid management.